Apolipoprotein e-deficient mice develop an anti-chlamydophila pneumoniae T helper 2 response and resist vascular infection

Journal of Infectious Diseases

Volumn 202, Issue 5, 2010, Pages 782-790

  Nazzal, Dani ^a   Therville, Nicole ^a   Yacoub Youssef, Houda ^a   Garcia, Virginie ^a   Thomsen, Mogens ^a   Levade, Thierry ^a   Segui, Bruno ^a   Benoist, Hervé ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; AORTA; ARTICLE; B LYMPHOCYTE; CHLAMYDIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; HYPERCHOLESTEROLEMIA; IMMUNE RESPONSE; INFECTION RESISTANCE; INFECTION SENSITIVITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH2 CELL;

ANIMALS; AORTA; APOLIPOPROTEINS E; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; HYPERCHOLESTEROLEMIA; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PNEUMONIA, BACTERIAL; TH2 CELLS; VASCULAR DISEASES;

EID: 77955666158     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/655700     Document Type: Article

References (42)

1. Belland RJ, Ouellette SP, Gieffers J, Byrne GI. Chlamydia pneumoniae and atherosclerosis. Cell Microbiol 2004; 6:117-127.
2. Netea MG, Kullberg BJ, Jacobs LE, et al. Chlamydia pneumoniae stimulates IFN-g synthesis through MyD88-dependent, TLR2- and TLR4- independent induction of IL-18 release. J Immunol 2004; 173:1477-1482.
3. Rothfuchs AG, Kreuger MR, Wigzell H, Rottenberg ME.Macrophages, CD4+ or CD8+ cells are each sufficient for protection against Chlamydia pneumoniae infection through their ability to secrete IFN-g. J Immunol 2004; 172:2407-2415.
4. Mpiga P, Ravaoarinoro M. Chlamydia trachomatis persistence: an update. Microbiol Res 2006; 161:9-19.
5. Ramsey KH, Miranpuri GS, Sigar IM, Ouellette S, Byrne GI. Chlamydia trachomatis persistence in the female mouse genital tract: inducible nitric oxide synthase and infection outcome. Infect Immun 2001; 69: 5131-5137.
6. Mannonen L, Kamping E, Penttila T, Puolakkainen M. IFN-g induced persistent Chlamydia pneumoniae infection in HL and Mono Mac 6 cells: characterization by real-time quantitative PCR and culture. Microb Pathog 2004; 36:41-50.
7. Caspar-Bauguil S, Puissant B, Nazzal D, et al. Chlamydia pneumoniae induces interleukin-10 production that down-regulates major histocompatibility complex class I expression. J Infect Dis 2000; 182:1394-1401.
8. Fan P, Dong F, Huang Y, Zhong G. Chlamydia pneumoniae secretion of a protease-like activity factor for degrading host cell transcription factors is required for major histocompatibility complex antigen expression. Infect Immun 2002; 70:345-349.
9. Byrne GI, Ojcius DM. Chlamydia and apoptosis: life and death decisions of an intracellular pathogen. Nat Rev Microbiol 2004; 2:802-808.
10. Carabeo RA, Mead DJ, Hackstadt T. Golgi-dependent transport of cholesterol to the Chlamydia trachomatis inclusion. Proc Natl Acad Sci U S A 2003; 100:6771-6776.
11. Benagiano M, Azzurri A, Ciervo A, et al. T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A 2003; 100:6658-6663.
12. Byrne GI, Kalayoglu MV. Chlamydia pneumoniae and atherosclerosis: links to the disease process. Am Heart J 1999; 138:S488-S490.
13. Nazzal D, Cantero AV, Therville N, et al. Chlamydia pneumoniae alters mildly oxidized low-density lipoprotein-induced cell death in human endothelial cells, leading to necrosis rather than apoptosis. J Infect Dis 2006; 193:136-145.
14. Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo CC. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. J Infect Dis 1999; 180:238-241.
15. Aalto-Setälä K, Laitinen K, Erkkilä L, et al. Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein Edeficient mice. Arterioscler Thromb Vasc Biol 2001; 21:578-584.
16. Caligiuri G, Rottenberg M, Nicoletti A, Wigzell H, Hansson GK. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation 2001; 103:2834-2838.
17. Hansson GK, Zhou X, Tornquist E, Paulsson G. The role of adaptive immunity in atherosclerosis. Ann N Y Acad Sci 2000; 902:53-62.
18. Laskowitz DT, Lee DM, Schmechel D, Staats HF. Altered immune responses in apolipoprotein E-deficient mice. J Lipid Res 2000; 41:613-620.
19. Roselaar SE, Daugherty A. Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J Lipid Res 1998; 39:1740-1743.
20. de Bont N, Netea MG, Demacker PN, Kullberg BJ, van der Meer JW, Stalenhoef AF. Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur J Clin Invest 2000; 30: 818-822.
21. Vonk AG, De Bont N, Netea MG, et al. Apolipoprotein-E-deficient mice exhibit an increased susceptibility to disseminated candidiasis. Med Mycol 2004; 42:341-348.
22. Ludewig B, Jaggi M, Dumrese T, et al. Hypercholesterolemia exacerbates virus-induced immunopathologic liver disease via suppression of antiviral cytotoxic T cell responses. J Immunol 2001; 166:3369-3376.
23. Martens GW, Arikan MC, Lee J, Ren F, Vallerskog T, Kornfeld H. Hypercholesterolemia impairs immunity to tuberculosis. Infect Immun 2008; 76:3464-3472.
24. Gaydos CA, Quinn TC, Eiden JJ. Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene. J Clin Microbiol 1992; 30:796-800.
25. Rottenberg ME, Gigliotti Rothfuchs AC, Gigliotti D, Svanholm C, Bandholtz L, Wigzell H. Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice. J Immunol 1999; 162:2829-2836.
26. Majlessi L, Lo-Man R, Leclerc C. Regulatory B and T cells in infections. Microbes Infect 2008; 10:1030-1035.
27. Zhang X, Deriaud E, Jiao X, Braun D, Leclerc C, Lo-Man R. Type I interferons protect neonates from acute inflammation through interleukin 10-producing B cells. J Exp Med 2007; 204:1107-1118.
28. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. J Immunol 2009; 182:7459-7472.
29. Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol 2008; 20:149-157.
30. Bouaziz JD, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 2008; 224:201-214.
31. Campbell LA, Blessing E, Rosenfeld M, Lin T, Kuo C. Mouse models of C. pneumoniae infection and atherosclerosis. J Infect Dis 2000; 181(suppl 3):S508-S513.
32. Meir KS, Leitersdorf E. Atherosclerosis in the apolipoprotein-E-deficient mouse: a decade of progress. Arterioscler Thromb Vasc Biol 2004; 24:1006-1014.
33. Rottenberg ME, Gigliotti Rothfuchs A, Gigliotti D, et al. Regulation and role of IFN-g in the innate resistance to infection with Chlamydia pneumoniae. J Immunol 2000; 164:4812-4818.
34. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000; 1: 475-482.
35. Belperron AA, Dailey CM, Bockenstedt LK. Infection-inducedmarginal zone B cell production of Borrelia hermsii-specific antibody is impaired in the absence of CD1d. J Immunol 2005; 174:5681-5686.
36. Grainger DJ, Reckless J, McKilligin E. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol 2004; 173:6366-6375.
37. Ali K, Middleton M, Puré E, Rader DJ. Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ Res 2005; 97:922-927.
38. Robertson AK, Zhou X, Strandvik B, Hansson GK. Severe hypercholesterolaemia leads to strong Th2 responses to an exogenous antigen. Scand J Immunol 2004; 59:285-293.
39. Yacoub-Youssef H, Blaes N, Calise D, et al. Interleukin-6 deficiency fails to prevent chronic rejection after aortic allografts in apolipoprotein E-deficient mice. J Heart Lung Transplant 2009; 28:85-92.
40. Kuo CC, Campbell LA, Rosenfeld ME. Chlamydia pneumoniae infection and atherosclerosis: methodological considerations. Circulation 2002; 105:E34.
41. Blessing E, Kuo CC, Lin TM, et al. Foam cell formation inhibits growth of Chlamydia pneumoniae but does not attenuate Chlamydia pneumoniae- induced secretion of proinflammatory cytokines. Circulation 2002; 105:1976-1982.
42. Meijer A, Roholl PJ, Gielis-Proper SK, Ossewaarde JM. Chlamydia pneumoniae antigens, rather than viable bacteria, persist in atherosclerotic lesions. J Clin Pathol 2000; 53:911-916.